Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.8.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenue:      
Contract research revenue $ 149,687 $ 194,494
Costs and Expenses:      
Research and development 9,010,499 3,947,644 5,292,193
General and administrative 7,641,592 4,309,489 4,813,800
Total costs and expenses 16,652,091 8,257,133 10,105,993
Loss from operations (16,502,404) (8,257,133) (9,911,499)
Sale of New Jersey net operating loss 636,927 674,901 756,472
Other income/(expense), net 22,032 (16,505) 19,627
Benefit for income taxes 356,956
Net loss (15,486,489) (7,598,737) (9,135,400)
Dividend to preferred shareholders (608,343)
Convertible preferred stock beneficial conversion feature accreted as a deemed dividend (4,393,809)
Inducement Charge from exercise of warrants (16,741,356)
Net loss attributable to common shareholders $ (32,836,188) $ (11,992,546) $ (9,135,400)
Net loss available for common shareholders per share : Basic and diluted $ (0.36) $ (0.21) $ (0.18)
Weighted average common shares outstanding:      
Basic and diluted 90,475,035 57,654,830 51,481,002